On November 4, 2026 Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, reported it will present clinical data from the Phase 1b/2 study of OP-3136 in combination with fulvestrant, the Phase 1b/2 study of palazestrant in combination with everolimus, and the Phase 1b study of palazestrant in combination with atirmociclib in poster presentations at the San Antonio Breast Cancer Symposium (SABCS) taking place December 8-11 in San Antonio, TX.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation Details
Title: A phase 1 study of OP-3136, a novel oral selective KAT6A/B inhibitor, as monotherapy and in combination with endocrine therapy (ET) in estrogen receptor-positive (ER+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC)
Abstract Number: 3363
Presentation Number: P1-4-16
Date/Time: Wednesday, December 9, 2026, 12:30 PM – 2:00 PM CT/11:30 AM – 1:00 PM ET
Title: Palazestrant (OP-1250) in combination with everolimus, a phase 1b/2 study, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer
Abstract Number: 813
Presentation Number: P4-13-28
Date/Time: Thursday, December 10, 2026, 5:00 PM – 6:30 PM CT/6:00 PM – 7:30 PM ET
Title: Palazestrant (OP-1250) in combination with atirmociclib, a phase 1b study, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer
Abstract Number: 811
Presentation Number: PS10-11
Date/Time: Friday, December 11, 2026, 7:00 AM – 8:30 AM CT/8:00 AM – 9:30 AM ET
Additional information can be found on the SABCS website. A copy of the posters will be made available on the Publications page of Olema’s website in alignment with the SABCS 2026 embargo policy.
(Press release, Olema Oncology, NOV 4, 2026, https://www.globenewswire.com/news-release/2026/11/04/3395781/0/en/olema-oncology-to-present-combination-data-from-the-palazestrant-and-op-3136-programs-at-the-2026-san-antonio-breast-cancer-symposium.html [SID1234674239])